Relation of Aspirin Failure to Clinical Outcome and to Platelet Response to Aspirin in Patients With Acute Myocardial Infarction

Beigel, Roy; Hod, Hanoch; Fefer, Paul; Asher, Elad; Новиков, Ю В; Шенкман, Борис; Savion, N.; Varon, David; Matetzky, Shlomi

doi:10.1016/j.amjcard.2010.09.025

Cited by 20 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the proven role of platelets in cardiovascular disease , and its treatment with aspirin, consideration of aspirin resistance and its adverse consequences (in terms of thrombosis) is frustrated by lack of consensus and the many methods to define this resistance . Flow cytometry offers the opportunity to improve on the most common method (LTA), but suffers from poor inter‐laboratory standardization and agreement on the meaning of aspirin resistance .…”

Section: Discussionmentioning

confidence: 99%

Vascular and platelet responses to aspirin in patients with coronary artery disease

Blann

Kuzniatsova

Lip

2012

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Vascular and platelet responses to aspirin in patients with coronary artery disease

Blann

Kuzniatsova

Lip

2012

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Nonetheless, some patients' platelets remain reactive despite aspirin therapy when assessed by in vitro laboratory tests using a variety of platelet agonists. Multiple studies have found these patients to be at higher risk of atherothrombotic events [61–65]. The problem is particularly prominent in DM patients, 10%–40% of whom display high residual platelet reactivity on biochemical testing despite aspirin therapy [66, 67].…”

Section: Clinical Implications Of Platelet Hyper-reactivity In Diamentioning

confidence: 99%

Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective

Kakouros

Rade

Kourliouros

et al. 2011

International Journal of Endocrinology

151

143

View full text Add to dashboard Cite

Patients with diabetes mellitus have an increased prevalence of vascular disease. Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of morbidity and mortality. Platelets are intimately involved in the initiation and propagation of thrombosis. Evidence suggests that platelets from patients with type 2 diabetes have increased reactivity and baseline activation compared to healthy controls. We review the pathophysiology of platelet hyperreactivity in DM patients and its implications in clinical practice, with particular focus on acute coronary syndromes, percutaneous coronary intervention, and novel antiplatelet agents.

show abstract

“…In the present study, a low response to aspirin was not associated with MACCEs in the overall patient group; however, subgroup analysis showed that a low response to aspirin was an independent predictor of long-term MACCEs in patients less than 70 years old (RR, 2.58; 95% CI: 1.04-6.28; p = 0.041). In fact, the patients in previous studies [23][24][25][26][27][28] who had a low response to aspirin associated with a poor clinical outcome were younger than the patients in this study. It could be speculated that the low response to aspirin is a risk factor of MACCEs in patients in this age criteria.…”

Section: Incidence Of Macces In Subgroup Of Patients Aged 70 Years Anmentioning

confidence: 43%

Impact of Platelet Reactivity on Long-term Clinical Outcomes and Bleeding Events in Japanese Patients Receiving Antiplatelet Therapy with Aspirin

Yamane¹,

Ikeda²,

Taniguchi³

et al. 2012

JAT

View full text Add to dashboard Cite

Aim:Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events. A low response to aspirin was reported to correlate with poor prognosis in patients undergoing antiplatelet therapy with aspirin. The aim of this study was to evaluate the impact of the antiplatelet activity of aspirin on cardiovascular and bleeding events in Japanese patients. Methods: We analyzed the clinical course of 239 Japanese patients undergoing antiplatelet therapy with aspirin for a median of 64 months in this study. Their residual platelet reactivity was examined at enrollment and after 2 years. The co-primary endpoints were the occurrence of major adverse cardiac and cerebrovascular events (MACCEs) and bleeding events. Results: The annual incidence of MACCEs and major bleeding events was 3.7% and 0.48%, respectively. With defined criteria, 67 patients (28%) were classified as low responders based on the platelet aggregability measured at enrollment. Low response to aspirin was not associated with increased MACCEs, while it clearly increased MACCEs in patients less than 70 years old (low responders 36.9% vs. responders 14.8%, log rank p=0.008). Five major types of bleeding occurred in the responders, but not in low responders, although the difference was not statistically significant (p = 0.07). Conclusion: Low response to aspirin was not associated with the increase of long-term MACCEs, while it increased MACCEs in patients less than 70 years old; however, it tended to decrease major bleeding events in Japanese patients.

show abstract

Relation of Aspirin Failure to Clinical Outcome and to Platelet Response to Aspirin in Patients With Acute Myocardial Infarction

Cited by 20 publications

References 24 publications

Vascular and platelet responses to aspirin in patients with coronary artery disease

Vascular and platelet responses to aspirin in patients with coronary artery disease

Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective

Impact of Platelet Reactivity on Long-term Clinical Outcomes and Bleeding Events in Japanese Patients Receiving Antiplatelet Therapy with Aspirin

Contact Info

Product

Resources

About